This discrepancy could be due to the use of Matrigel to inoculate tumor cells and the CD4−/− mouse model, which could alter the tumor microenvironment and disrupt the interactions occurring between CD4+ and CD8+ T cells during tumor initiation and progression. This evidence concerns the gene CD4 and neoplasm.